GeNeuro SA engages in the research and development of treatments against neurological disorders and autoimmune disease. The firm's lead therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic human endogenous retroviruses (HERV) protein of the W family called pHERV-W env that has been identified as a factor in the onset and development of autoimmune diseases. The company was founded by Herve Perron and Jesus Martin-Garcia in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. GeNeuro SA market cap is $113.32M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. GeNeuro SA 52 week high is $4.55 as of November 18, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. GeNeuro SA 52 week low is $4.55 as of November 18, 2026.
GeNeuro SA stock price today is $4.55.
GeNeuro SA stock price yesterday was $4.55.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. GeNeuro SA's P/E ratio is -10.13.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. GeNeuro SA P/B ratio is 14.2866.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. GeNeuro SA 50-day moving average is $4.55.